Bionano Genomics Inc. (NASDAQ: BNGO) is 74.03% higher on its value in year-to-date trading and has touched a low of $0.25 and a high of $7.24 in the current 52-week trading range. The BNGO stock was last observed hovering at around $5.67 in the last trading session, with the day’s loss setting it -0.31% off its average median price target of $1.38 for the next 12 months. It is also -168.0% off the consensus price target high of $2.00 offered by 4 analysts, but current levels are -614.67% lower than the price target low of $0.75 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $5.36, the stock is 136.29% and 342.22% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 59.65 million and changing -5.47% at the moment leaves the stock 659.21% off its SMA200. BNGO registered 354.24% gain for a year compared to 6-month gain of 991.65%. The firm has a 50-day simple moving average (SMA 50) of $1.57 and a 200-day simple moving average (SMA200) of $0.84.
The stock witnessed a 982.83% loss in the last 1 month and extending the period to 3 months gives it a 797.67%, and is 8.28% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 18.88% over the week and 22.61% over the month.
Bionano Genomics Inc. (BNGO) has around 97 employees, a market worth around $873.47M and $7.30M in sales. Distance from 52-week low is 2044.00% and -25.97% from its 52-week high. The company has generated returns on investments over the last 12 months (-114.90%).
Bionano Genomics Inc. (BNGO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Bionano Genomics Inc. (BNGO) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 1.70, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Bionano Genomics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.06 with sales reaching $2.92M over the same period.The EPS is expected to shrink by -8.20% this year, but quarterly earnings will post -26.40% year-over-year. Quarterly sales are estimated to grow 4.70% in year-over-year returns.
Bionano Genomics Inc. (BNGO) Top Institutional Holders
27 institutions hold shares in Bionano Genomics Inc. (BNGO), with 87.32k shares held by insiders accounting for 0.06% while institutional investors hold 5.64% of the company’s shares. The shares outstanding are 153.19M, and float is at 150.99M with Short Float at 5.62%. Institutions hold 5.64% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 5.57 million shares valued at $3.62 million. The investor’s holdings represent 3.63% of the BNGO Shares outstanding. As of Sep 29, 2020, the second largest holder is Bank Julius Baer & Co. Ltd, Zurich with 0.85 million shares valued at $0.55 million to account for 0.55% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 0.62 million shares representing 0.40% and valued at over $0.4 million, while Perkins Capital Management, Inc. holds 0.31% of the shares totaling 0.47 million with a market value of $0.31 million.
Bionano Genomics Inc. (BNGO) Insider Activity
A total of 0 insider transactions have happened at Bionano Genomics Inc. (BNGO) in the last six months, with sales accounting for 0 and purchases happening 0 times.